GSK vs JNJ: Which Is the Better Dividend Stock?
As of July 2026, JNJ (Johnson & Johnson) screens as the stronger dividend stock, winning 5 of 8 head-to-head metrics. GSK offers the higher yield at 3.50%, JNJ has the higher dividend-safety score, and GSK trades at the larger discount to fair value (+10%).
| Metric | GSK | JNJ |
|---|---|---|
| Forward yield | 3.50% | 2.03% |
| Annual dividend | $1.80 | $5.36 |
| Payout ratio | 47% | 61% |
| Years of growth | 2 yr | 55 yr |
| 5-yr dividend growth | -4.0% | 5.2% |
| 5-yr total return | 26% | 52% |
| Dividend safety score | 54 (C) | 93 (A) |
| Fair value estimate | $56.55 | $229.97 |
| Upside to fair value | +10% | -13% |
| Frequency | quarterly | quarterly |
| Market cap | $102.8B | $634.8B |
| P/E ratio | 13.5 | 30.6 |
Higher yield
GSK
3.50%
Safer dividend
JNJ
Grade A
Faster growth
JNJ
5.2%
Better value
GSK
+10% upside
GSK vs JNJ — FAQ
Related comparisons
See more dividend stock comparisons · data refreshes daily · for informational purposes only, not investment advice.